This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Bruker Corp (BRKR) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Headquartered in Billerica, MA, Bruker Corporation (BRKR) scaled a new 52-week high of $27.85 on May 22, eventually closing a bit lower at $26.62.
Integra Lifesciences Hits 52-Week High on Product Launches
by Zacks Equity Research
Share price of Plainsboro NJ-based Integra Lifesciences Corporation (IART) reached a new 52-week high of $47.50 on May 19, finally closing a tad lower at $47.39.
Intuitive Surgical at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Sunnyvale, CA-based Intuitive Surgical Inc (ISRG) scaled a new 52-week high of $874.54 on May 19, eventually closing a bit lower at $870.33.
Quality Systems (QSII) Beats Q4 Earnings, Issues FY18 View
by Zacks Equity Research
Irvine, CA-based Quality Systems Inc. (QSII) reported fourth-quarter fiscal 2017 adjusted earnings of 18 cents per share, exceeding the Zacks Consensus Estimate by a penny. Earnings remained flat on a year-over-year basis.
McKesson (MCK) Beats Earnings Estimate in Q4, Revenues Miss
by Zacks Equity Research
McKesson Corporation (MCK) reported fourth-quarter fiscal 2017 earnings of $3.39 per share, beating the Zacks Consensus Estimate of $3.04.
Halyard Health-Sustainable Solutions Ink License Agreement
by Zacks Equity Research
Halyard Health (HYH) announced a new license and supply agreement with Sustainable Solutions. The license agreement is aimed at converting recycled HALYARD Wrap into an environment friendly product for healthcare facilities.
Hill Rom Impresses with Q2 Results, Strategic Initiatives
by Zacks Equity Research
On May 18, we issued an updated research report on Hill Rom Holdings, Inc. (HRC).
Mazor Robotics at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Shares of Israel-based developer of robotic technology and products, Mazor Robotics Ltd. (MZOR), rallied to a new 52-week high of $45.64 on May 18.
Exactech (EXAC) Gets FDA Approval for ExactechGPS Application
by Zacks Equity Research
Exactech Inc. (EXAC) recently announced that it has received clearance from the U.S. Food and Drug Administration to market its proprietary ExactechGPS Shoulder Application in US.
Boston Scientific's Symetis Buyout Boosts Structural Heart
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently completed the acquisition of Switzerland-based Symetis SA.